AC Immune Signs With Janssen Pharmaceuticals for Alzheimer’s Disease Treatment Using Anti-Tau Vaccination

AC Immune Signs With Janssen Pharmaceuticals for Alzheimer’s Disease Treatment Using Anti-Tau Vaccination
AC Immune SA recently announced it has signed an exclusive worldwide license agreement and collaboration contract with Janssen Pharmaceuticals, Inc. to develop and commercialize anti-Tau vaccines to treat Alzheimer’s disease. According to the contract, Janssen Research & Development, an affiliate of Janssen Pharmaceuticals, Inc., will advance the development of the vaccine ACI-35 which is currently going through a Phase Ib clinical trial in patients suffering from this common form of dementia. The ACI-35 vaccine works to stimulate the immune system so it produces a polyclonal antibody response against the phosphorylated Tau protein. AC Immune will receive an upfront payment and will be eligible to receive development, research and commercialization payments for the purpose of addressing Alzheimer's disease. The two companies will co-develop ACI-35 during Phase Ib. Come Phase II onwards, Jansen will assume the responsibility of carrying out the vaccine's clinical advancement, manufacturing, and commercialization. Andrea Pfeifer, AC Immune's CEO said in a pr
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *